- Current report filing (8-K)
23 June 2010 - 7:02AM
Edgar (US Regulatory)
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): June 17, 2010
TIENS
BIOTECH GROUP (USA), INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-32477
|
75-2926439
|
(State or other
jurisdiction
|
(Commission File
Number)
|
(I.R.S.
Employer
|
of
incorporation)
|
|
Identification
Number)
|
N
o. 6, Yuanquan Road, Wuqing
New-Tech Industrial Park, Tianjin, China
301700
(Address
of principal executive offices)
Registrant's
telephone number, including area code:
(
86)
22
-
8213-
7335
Not
applicable
(Former
name or former address, if changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2.):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 5.02
Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain
Officers.
On June
17, 2010, Tiens Biotech Group (USA), Inc. (the “Company”) received notification
from Manbo He that effective immediately, he resigned from his positions as
Chief Financial Officer and Director of the Company. There were no
disagreements between Mr. He and the Company on any matter relating to the
Company’s operations, policies or practices, which resulted in his
resignation.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
TIENS BIOTECH GROUP (USA),
INC.
|
|
|
|
|
|
|
|
|
Date: June
18, 2010
|
By:
|
/s/ Jinyuan
Li
|
|
|
|
Name:
Jinyuan Li
|
|
|
|
Title:
Chairman, Chief Executive Officer and
President
|
Tiens Biotech GR Usa (AMEX:TBV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tiens Biotech GR Usa (AMEX:TBV)
Historical Stock Chart
From Sep 2023 to Sep 2024